Diana M Sobieraj1, William L Baker1, Elaine Nguyen1, Erin R Weeda1, Craig I Coleman1, C Michael White1, Stephen C Lazarus2, Kathryn V Blake3, Jason E Lang4. 1. Department of Pharmacy Practice, University of Connecticut School of Pharmacy, Storrs. 2. Division of Pulmonary and Critical Care Medicine, University of California, San Francisco. 3. Center for Pharmacogenomics and Translational Research, Nemours Children's Specialty Care, Jacksonville, Florida. 4. Division of Allergy, Immunology, and Pulmonary Medicine, Duke University School of Medicine, Duke Children's Hospital and Health Center, Durham, North Carolina.
Abstract
Importance: Long-acting muscarinic antagonists (LAMAs) are a potential adjunct therapy to inhaled corticosteroids in the management of persistent asthma. Objective: To conduct a systematic review and meta-analysis of the effects associated with LAMA vs placebo or vs other controllers as an add-on therapy to inhaled corticosteroids and the use of a LAMA as add-on therapy to inhaled corticosteroids and long-acting β-agonists (LABAs; hereafter referred to as triple therapy) vs inhaled corticosteroids and LABA in patients with uncontrolled, persistent asthma. Data Sources: MEDLINE, EMBASE, Cochrane databases, and clinical trial registries (earliest date through November 28, 2017). Study Selection: Two reviewers selected randomized clinical trials or observational studies evaluating a LAMA vs placebo or vs another controller as an add-on therapy to inhaled corticosteroids or triple therapy vs inhaled corticosteroids and LABA in patients with uncontrolled, persistent asthma reporting on an outcome of interest. Data Extraction and Synthesis: Meta-analyses using a random-effects model was conducted to calculate risk ratios (RRs), risk differences (RDs), and mean differences (MDs) with corresponding 95% CIs. Citation screening, data abstraction, risk assessment, and strength-of-evidence grading were completed by 2 independent reviewers. Main Outcomes and Measures: Asthma exacerbations. Results: Of 1326 records identified, 15 randomized clinical trials (N = 7122 patients) were included. Most trials assessed adding LAMA vs placebo or LAMA vs LABA to inhaled corticosteroids. Adding LAMA vs placebo to inhaled corticosteroids was associated with a significantly reduced risk of exacerbation requiring systemic corticosteroids (RR, 0.67 [95% CI, 0.48 to 0.92]; RD, -0.02 [95% CI, -0.04 to 0.00]). Compared with adding LABA, adding LAMA to inhaled corticosteroids was not associated with significant improvements in exacerbation risk (RR, 0.87 [95% CI, 0.53 to 1.42]; RD, 0.00 [95% CI, -0.02 to 0.02]), or any other outcomes of interest. Triple therapy was not significantly associated with improved exacerbation risk vs inhaled corticosteroids and LABA (RR, 0.84 [95% CI, 0.57 to 1.22]; RD, -0.01 [95% CI, -0.08 to 0.07]). Conclusions and Relevance: In this systematic review and meta-analysis, the use of LAMA compared with placebo as add-on therapy to inhaled corticosteroids was associated with a lower risk of asthma exacerbations; however, the association of LAMA with benefit may not be greater than that with LABA. Triple therapy was not associated with a lower risk of exacerbations.
Importance: Long-acting muscarinic antagonists (LAMAs) are a potential adjunct therapy to inhaled corticosteroids in the management of persistent asthma. Objective: To conduct a systematic review and meta-analysis of the effects associated with LAMA vs placebo or vs other controllers as an add-on therapy to inhaled corticosteroids and the use of a LAMA as add-on therapy to inhaled corticosteroids and long-acting β-agonists (LABAs; hereafter referred to as triple therapy) vs inhaled corticosteroids and LABA in patients with uncontrolled, persistent asthma. Data Sources: MEDLINE, EMBASE, Cochrane databases, and clinical trial registries (earliest date through November 28, 2017). Study Selection: Two reviewers selected randomized clinical trials or observational studies evaluating a LAMA vs placebo or vs another controller as an add-on therapy to inhaled corticosteroids or triple therapy vs inhaled corticosteroids and LABA in patients with uncontrolled, persistent asthma reporting on an outcome of interest. Data Extraction and Synthesis: Meta-analyses using a random-effects model was conducted to calculate risk ratios (RRs), risk differences (RDs), and mean differences (MDs) with corresponding 95% CIs. Citation screening, data abstraction, risk assessment, and strength-of-evidence grading were completed by 2 independent reviewers. Main Outcomes and Measures: Asthma exacerbations. Results: Of 1326 records identified, 15 randomized clinical trials (N = 7122 patients) were included. Most trials assessed adding LAMA vs placebo or LAMA vs LABA to inhaled corticosteroids. Adding LAMA vs placebo to inhaled corticosteroids was associated with a significantly reduced risk of exacerbation requiring systemic corticosteroids (RR, 0.67 [95% CI, 0.48 to 0.92]; RD, -0.02 [95% CI, -0.04 to 0.00]). Compared with adding LABA, adding LAMA to inhaled corticosteroids was not associated with significant improvements in exacerbation risk (RR, 0.87 [95% CI, 0.53 to 1.42]; RD, 0.00 [95% CI, -0.02 to 0.02]), or any other outcomes of interest. Triple therapy was not significantly associated with improved exacerbation risk vs inhaled corticosteroids and LABA (RR, 0.84 [95% CI, 0.57 to 1.22]; RD, -0.01 [95% CI, -0.08 to 0.07]). Conclusions and Relevance: In this systematic review and meta-analysis, the use of LAMA compared with placebo as add-on therapy to inhaled corticosteroids was associated with a lower risk of asthma exacerbations; however, the association of LAMA with benefit may not be greater than that with LABA. Triple therapy was not associated with a lower risk of exacerbations.
Authors: Pierluigi Paggiaro; David M G Halpin; Roland Buhl; Michael Engel; Valentina B Zubek; Zuzana Blahova; Petra Moroni-Zentgraf; Emilio Pizzichini Journal: J Allergy Clin Immunol Pract Date: 2015-11-07
Authors: Michelle M Cloutier; Michael Schatz; Mario Castro; Noreen Clark; H William Kelly; Rita Mangione-Smith; James Sheller; Christine Sorkness; Stuart Stoloff; Peter Gergen Journal: J Allergy Clin Immunol Date: 2012-03 Impact factor: 10.793
Authors: Robert S Tepper; Robert S Wise; Ronina Covar; Charles G Irvin; Carolyn M Kercsmar; Monica Kraft; Mark C Liu; George T O'Connor; Stephen P Peters; Ronald Sorkness; Alkis Togias Journal: J Allergy Clin Immunol Date: 2012-03 Impact factor: 10.793
Authors: Huib A M Kerstjens; Thomas B Casale; Eugene R Bleecker; Eli O Meltzer; Emilio Pizzichini; Olaf Schmidt; Michael Engel; Loek Bour; Cynthia B Verkleij; Petra Moroni-Zentgraf; Eric D Bateman Journal: Lancet Respir Med Date: 2015-02-12 Impact factor: 30.700
Authors: Laurie A Lee; Shuying Yang; Edward Kerwin; Roopa Trivedi; Lisa D Edwards; Steven Pascoe Journal: Respir Med Date: 2014-10-02 Impact factor: 3.415
Authors: Eckard Hamelmann; Eric D Bateman; Christian Vogelberg; Stanley J Szefler; Mark Vandewalker; Petra Moroni-Zentgraf; Mandy Avis; Anna Unseld; Michael Engel; Attilio L Boner Journal: J Allergy Clin Immunol Date: 2016-03-05 Impact factor: 10.793
Authors: Mohamed S Al-Moamary; Sami A Alhaider; Abdullah A Alangari; Mohammed O Al Ghobain; Mohammed O Zeitouni; Majdy M Idrees; Abdullah F Alanazi; Adel S Al-Harbi; Abdullah A Yousef; Hassan S Alorainy; Mohamed S Al-Hajjaj Journal: Ann Thorac Med Date: 2019 Jan-Mar Impact factor: 2.219
Authors: Jorine E Hartman; Karthi Srikanthan; Cielito Caneja; Nick H T Ten Hacken; Huib A M Kerstjens; Pallav L Shah; Dirk-Jan Slebos Journal: Respiration Date: 2021-09-01 Impact factor: 3.966
Authors: John Blakey; Li Ping Chung; Vanessa M McDonald; Laurence Ruane; John Gornall; Chris Barton; Sinthia Bosnic-Anticevich; John Harrington; Mark Hew; Anne E Holland; Trudy Hopkins; Lata Jayaram; Helen Reddel; John W Upham; Peter G Gibson; Philip Bardin Journal: Respirology Date: 2021-09-29 Impact factor: 6.175
Authors: Alan Kaplan; J Mark FitzGerald; Roland Buhl; Christian Vogelberg; Eckard Hamelmann Journal: NPJ Prim Care Respir Med Date: 2020-11-11 Impact factor: 2.871